Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ai-Ming Yu

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Theranostics|July 10, 2020
A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesisYixin Chen, Yanying Zhou, Fangwei Han, et al.
Oncotarget|April 19, 2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsChao Jian, Mei-Juan Tu, Pui Yan Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2018
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer TherapyPui Yan Ho, Zhijian Duan, Neelu Batra, et al.
Cancers|February 25, 2022
The Cationic Amphiphilic Drug Hexamethylene Amiloride Eradicates Bulk Breast Cancer Cells and Therapy-Resistant Subpopulations with Similar EfficienciesAnastasia L Berg, Ashley Rowson-Hodel, Michelle Hu, et al.
Clinical Pharmacology and Therapeutics|August 24, 2022
DNA-Thioguanine Nucleotides as a Marker for Thiopurine Induced Late Leukopenia after Dose Optimizing by NUDT15 C415T in Chinese Patients with IBDXia Zhu, Kang Chao, Ting Yang, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancerJustin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
Nature Communications|January 4, 2024
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapyZhangyi Luo, Yixian Huang, Neelu Batra, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 30, 2015
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional CharacterizationWei-Peng Wang, Pui Yan Ho, Qiu-Xia Chen, et al.
Acta Pharmaceutica Sinica. B|April 8, 2017
Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21<sup>st</sup> International Symposium on Microsomes and Drug Oxidations (MDO)Ai-Ming Yu, Magnus Ingelman-Sundberg, Nathan J Cherrington, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Theranostics|July 10, 2020
A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesisYixin Chen, Yanying Zhou, Fangwei Han, et al.
Oncotarget|April 19, 2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsChao Jian, Mei-Juan Tu, Pui Yan Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2018
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer TherapyPui Yan Ho, Zhijian Duan, Neelu Batra, et al.
Cancers|February 25, 2022
The Cationic Amphiphilic Drug Hexamethylene Amiloride Eradicates Bulk Breast Cancer Cells and Therapy-Resistant Subpopulations with Similar EfficienciesAnastasia L Berg, Ashley Rowson-Hodel, Michelle Hu, et al.
Clinical Pharmacology and Therapeutics|August 24, 2022
DNA-Thioguanine Nucleotides as a Marker for Thiopurine Induced Late Leukopenia after Dose Optimizing by NUDT15 C415T in Chinese Patients with IBDXia Zhu, Kang Chao, Ting Yang, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancerJustin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
Nature Communications|January 4, 2024
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapyZhangyi Luo, Yixian Huang, Neelu Batra, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 30, 2015
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional CharacterizationWei-Peng Wang, Pui Yan Ho, Qiu-Xia Chen, et al.
Acta Pharmaceutica Sinica. B|April 8, 2017
Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21<sup>st</sup> International Symposium on Microsomes and Drug Oxidations (MDO)Ai-Ming Yu, Magnus Ingelman-Sundberg, Nathan J Cherrington, et al.
Pageof 14